Search by Drug Name or NDC
NDC 00002-3002-01 MOUNJARO 15 mg/.5mL Details
MOUNJARO 15 mg/.5mL
MOUNJARO is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is TIRZEPATIDE.
Product Information
| NDC | 00002-3002 |
|---|---|
| Product ID | 0002-3002_b597917f-9673-4331-809d-79a538bb943c |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | MOUNJARO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | tirzepatide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 15 |
| Active Ingredient Units | mg/.5mL |
| Substance Name | TIRZEPATIDE |
| Labeler Name | Eli Lilly and Company |
| Pharmaceutical Class | G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA215866 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00002-3002-01 (00002300201)
| NDC Package Code | 0002-3002-01 |
|---|---|
| Billing NDC | 00002300201 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-3002-01) / .5 mL in 1 VIAL, SINGLE-DOSE |
| Marketing Start Date | 2023-07-28 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |